Loading...
Standardization and evaluation of an Anti-ZIKV IgM ELISA assay for the serological diagnosis of zika virus infection
Author(s)
Sirikajornpan, Kanittha
Suntarattiwong, Piyarat
Suwanpakdee, Detchvijitr
Tabprasit, Sutchana
Buddhari, Darunee
Thaisomboonsuk, Butsaya
Klungthong, Chonticha
Poolpanichupatam, Yongyuth
Buathong, Rome
Jones, Anthony
Fernandez, Stefan
Hunsawong, Taweewun
Date Issued
October 1, 2021
Type
Article
Abstract
Here, we describe the development of the in-house anti-Zika virus (ZIKV) IgM antibody capture ELISA (in-house ZIKV IgM ELISA) for the detection and diagnosis of acute ZIKV infections. We compared the in-house ZIKV IgM ELISA assay performance against two commercial kits, Euroimmun ZIKV IgM and InBios 2.0 ZIKV IgM ELISA. We tested the assays' ability to detect anti-ZIKV IgM using a well-defined serum sample panel. This panel included 80 ZIKV negative samples (20 negative, 20 found to be primary dengue virus [DENV][ infections, 20 secondary DENV infections, and 20 Japanese encephalitis virus [JEV] infections) and 67 ZIKV reverse transcriptase-polymerase chain reaction-positive acute serum samples. The OD values were calculated to enzyme immunoassay (EIA) unts by comparing them to weak positive controls. The results demonstrated the high sensitivity (88.06%) and specificity (90.00%) of our in-house ZIKV IgM ELISA and its 89.12% overall percentage agreement. The kappa values were deemed to be within excellent range and comparable to the InBios ZIKV IgM ELISA. Some cross-reactivity was observed among secondary DENV and JEV samples, and to a much lower extent, among primary DENV samples. These data indicate that our in-house ZIKV IgM ELISA is a reliable assay for the detection of anti-ZIKV IgM antibodies in serum.
Citation
American Journal of Tropical Medicine and Hygiene, 105(4), 936-941, 2021